N,o-(2,3-dihydroxypropyl)chitosanyl-borate, having antibacterial, immunomodulating and antitoxic effect
SUBSTANCE: invention relates to a novel compound - N,O-(2,3-dihydroxypropyl)chitosanyl-borate, having formula , where m=500-3000.
EFFECT: compound has antibacterial, immunomodulating and antitoxic effect.
1 tbl, 6 ex
The invention relates to the field of biologically active compounds and relates to a borate complex of the N,O-(2,3-dihydroxypropyl)chitosan, antibacterial, immunomodulatory and anti-toxic effect, intended for the prevention and treatment of severe forms of dyspepsia in animals is complicated by pathogenic forms of enterobacteria and cocci. The invention can be used in veterinary institutions, research laboratories, as well as in livestock and poultry.
Boric acid and its salts are widely used as components of external antiseptic drugs: pasta Teymurova, liniment "boron-zinc" ointment "Borno", solution "fukortsin", alcohol and glycerine solution of boric acid and sodium tetraborate in the compositions of creams, ointments for treating burns (Mashkovsky M. D. Medicines, Moscow, New wave, 2000). In addition, it is often used as a mild antiseptic in solutions for storing eye contact lenses. Known antibacterial agents based on boron compounds (WO 2013104897, WO 2013093615, WO 2013033461, WO 2011060196), borates (WO 2011056168, SU 201404) and boric acid (F. Haesebrouck, M. Baele, H. De Keyser. Antimicrobial activity of an acetic and boric acid solution against Staphylococcuspseudointermedius // Vlaams Diergeneeskundig Tijdschrin, 78 (2009). P. 89-90).
The drawback of such dosage forms is the presence�their free of boric acid and its molecular complexes with trivalent alcohols, aromatic hydroxycarboxylic acids and phenols and boron compounds, which provide a rapid supply of a therapeutic dose of boron ions (III) in the body, which, firstly, leads to rapid excretion of the drug, and secondly, may cause toxic effects if decompensation excretory capacity of the kidneys.
The closest analogue of the invention is a borate complex on the basis of the block copolymer carboxymethylchitin and polyglycerol (A. A. Alencar de Queiroz et all. Physicochemical and antimicrobial properties of boron-complexed polyglycerolchitosan of // J. Biomater. Sci Polymer Edn. 17 (2006). P. 689-707). To obtain it initially synthesize the polyglycerol by polymerization of glycidol in the presence of NaOH at 260°C and then at 120°C in vacuum for 24 hours. Next spend getting carboxymethylchitin by treating the chitosan with Chloroacetic acid in an aqueous solution of NaOH at 30°C for 12 hours, and then carry out the esterification carboxymethylchitin the polyglycerol when heated to reflux and the use of dimethyl sulfate as a catalyst. Next, the obtained blockcopolymer polyglycerol and carboxymethylchitin treated with boric acid at 160°C for 3 hours. The obtained polyglycerol-carboxymethylchitin-Borat has an antibacterial effect.
The disadvantages of this are complex with�agnosti its synthesis, consisting of four stages, using a long heating at high temperature. This explains its low commercial availability. In addition, the high viscosity of low-concentrated solutions causes inconvenience in their use and requires no additional fixing materials.
Object of the invention is obtaining a new connection - N,O-(2,3-dihydroxypropyl)chitosan-borate, antibacterial, immunomodulatory and anti-toxic effect simple and effective way using readily available substances.
The task is solved by obtaining the N,O-(2,3-dihydroxypropyl)chitosan-borate of the formula
by first obtaining N,O-(2,3-dihydroxypropyl)chitosan with a degree of substitution of 2.0 to 3.0 by the interaction of chitosan with an aqueous solution of glycidol in the presence of hydrochloric acid at 55-65°C for 12-14 hours (EN 2496793), then the interaction of N,O-(2,3-dihydroxypropyl)of chitosan with an aqueous solution of boric acid at pH 9 at a temperature of 20-30°C for 24 hours, followed by separation of the formed gel from the solution. The composition and structure of the obtained N,O-(2,3-dihydroxypropyl)chitosan-Borat characterize the data of elemental analysis, ft-IR spectroscopy.
Preparation of aqueous solution of N,O-(2,3-dihydroxypropyl)chitosan-Borat� is carried out by dilution of the gel to the desired concentration with distilled water.
Toxicological studies of N,O-(2,3-dihydroxypropyl)chitosan-Borat conducted on laboratory animals (white mice). The aqueous solution is administered to white mice (weighing 25-30 g) in the stomach with a syringe with an elastic probe. The animals are monitored for 2 weeks after the administration, given the General condition of the animals, the preservation of motor function, appetite, condition of coat, breathing, reaction to external stimuli.
Conducted study of the morphological composition of blood cells and biochemical indices of blood serum in the experimental group did not differ from those in control. Histological examination of internal organs from mice treated with the complex for 20 days, no changes were detected that characterizes the lack of toxic effect of the drug on the body. The maximum tolerated dose of N,O-(2,3-dihydroxypropyl)chitosan-Borat is 1600 mg/kg, preventive - 70 mg/kg, and therapeutic index (the ratio of these doses) is 22.8, which indicates a sufficient limit the safe use of N,O-(2,3-dihydroxypropyl)chitosan-Borat in veterinary medicine.
For bacteriostatic studies using bacterial cultures: Escherichia coli, Staphylococcus aureus, Klebsiella pneumonias, Staphylococcus epidermidis isolates from clinically ill animals with severe dyspepsia. Mi�Kalou inhibitory concentration (MIC) is determined, using serial solutions of N,O-(2,3-dihydroxypropyl)chitosan-Borat on mesopatamia broth. In each test tube add 50 µl of saline containing a suspension of bacteria at a concentration of 6*107CFU/ml Control serves as a vial containing pure culture medium. The effect of the concentration N,O-(2,3-dihydroxypropyl)chitosan-borate on growth dynamics of culture in a liquid medium, are examined by the modified method. To do this, 50 μl of cell suspension 18-hour culture of bacteria that contains 6*107CFU/ml was added to 100 μl mycopathologia agar containing N,O-(2,3-dihydroxypropyl)chitosan-borate at different concentrations and pH 6.0. In the control variant N,O-(2,3-dihydroxypropyl)chitosan-Borat is not added. The mixture was incubated at 37°C on a rocker at 180 rpm.
To assess the immunomodulatory, antimicrobial and antitoxic properties of the N,O-(2,3-dihydroxypropyl)chitosan-Borat conduct experiments concerning animals suffering from colibacillosis in cattle farming and dysfunctional in this disease. Experiments carried out on calves of the Holstein (black and white suit) rocks ranging in age from birth to one month. This forms two groups of newborn calves by 10 goals each.
Animals first experimental group at day old once � day asking N,O-(2,3-dihydroxypropyl)chitosan-borate in aqueous solution, dissolved in milk, and fed to calves within 15 days. Control calves left intact. Blood samples for biochemical studies take at the age of 1 day and 20 days. Observation of clinical status, growth and development of calves within 2 months with manifestations of diarrhea show that the calves of the control group significantly lag behind their peers. The intensity of the biomass growth of calves of the experimental group is higher than control, respectively, 13.8% at 30 days and 21.7% on the 60th day after the start of treatment. Thus, the calves fed for the treatment of N,O-(2,3-dihydroxypropyl)chitosan-Borat, have the greatest rate of growth in comparison with the control group. In Hematology the study of blood of the calves of the control group revealed significant changes, indicating the presence of acute inflammation in animals. In particular, the marked increase in the total number of cells by 69%, reduced number of red blood cells by 29.5%, and the number of hemoglobin by 36%, reduced levels of carotene by 27% calcium 34%, phosphorus by 21%, increased reserve alkalinity and total protein content in serum, exceeded the value of the ESR in 4 times. Such changes indicate a profound metabolic disorders and the occurrence of infectious-inflammatory processes in to�trolley group of animals. The effectiveness of the treatment of animals in the experimental group was 100% recovery of calves. In the control group died 2 calf out of 10.
Disinfectant properties of the N,O-(2,3-dihydroxypropyl)chitosan-Borat determined on contaminated test cultures (Escherichia coli, Staphylococcus aureus) objects. As test objects, using a wooden surface with porous structure. Contaminated test object is dried for one hour at room temperature, and then treated with an aqueous solution of N,O-(2,3-dihydroxypropyl)chitosan-Borat from the sprayer. The temperature of the working solution of the drug and the air during the experiments is 18-20°C, relative humidity 65-75%.
Obtaining N,O-(2,3-dihydroxypropyl)chitosan-Borat illustrated by the following examples.
10 g of powdered N,O-(2,3-dihydroxypropyl)chitosan with a molecular weight of 930 kDa (corresponding to the value of m=3000) with a degree of substitution of 2.0 is dissolved in 300 ml of water with pH=9 containing 2.25 g of boric acid, with stirring for 1 hour and allowed to stand for 23 hours at room temperature. The formed gel was separated from the solution. Found, %: 3,70; N 0,36; At 0.53. IR spectrum (cm-1): 3381 (N-H), (O-H), 2922 (C-H), 1660 (C=O amide I), 1568 (N-H amide II), 1435 (C-H), 1372 (C-N amide III), 1150 (C-O), (C-C), 1067 (C-O), (P-C).
10 g of powdered N,O-(2,3-dihydroxypropyl)hit�Zan with a molecular weight of 193 kDa (corresponding to the value of m=500) with a degree of substitution of 3.0 is dissolved in 200 ml of water with pH=9, containing 1.5 g of boric acid, with stirring for 1 hour, then add 100 ml of water with pH=9 containing 0.75 g of boric acid, stirred for 1 hour and incubated for 22 hours at room temperature. The formed gel was separated from the solution. Found, %: 4,63; N 0,45; 0,93. IR spectrum (cm-1): 3381 (N-H), (O-H), 2922 (C-H), 1660 (C=O amide I), 1568 (N-H amide II), 1435 (C-H), 1372 (C-N amide III), 1150 (C-O), (C-C), 1067 (C-O), (P-C).
The use of N,O-(2,3-dihydroxypropyl)chitosan-borate in the form of a solution
0.9 g N,O-(2,3-dihydroxypropyl)chitosan-borate obtained in example 2, was dissolved at 29.1 ml of water, the resulting solution is diluted with the required amount of milk and fed the newborn animal at day old. The procedure was repeated 1 times a day for 15 days.
1.8 g of N,O-(2,3-dihydroxypropyl)chitosan-borate obtained in example 1, was dissolved at 58.2 ml of water, the resulting solution is diluted with the necessary quantity of milk or added to dry food, animal feed, at the age of 1 year. The procedure was repeated 1 times a day for 15 days.
1.8 g of N,O-(2,3-dihydroxypropyl)chitosan-borate obtained in example 2, was dissolved at 58.2 ml of water, the resulting solution is impregnated gauze swabs and fill their wounds. Drainage is to retain the appearance of granulation tissue on the affected surface.
Used�a lo g N,O-(2,3-dihydroxypropyl)chitosan-borate in the form of a gel
Surgical instruments made of alloys and polymers immersed in an aqueous gel obtained in example 2 for 3 hours. After bactericidal treatment items washed in water with surface-active substance.
A method of producing N,O-(2,3-dihydroxypropyl)chitosan-Borat simple in design, requires the use of commercially available compounds, can significantly reduce the amount of used organic solvents as in the modification process, and in the process of selection of the product, consists of two stages and does not require prolonged heating at a high temperature.
An aqueous solution of N,O-(2,3-dihydroxypropyl)chitosan-Borat has the consistency of a gel that provides the ease of use. Advantages of the claimed compounds is the use of biosecurity and biocompatible polymers, which ensures, first, the lack of toxicity to the living body - all components are substances 4 hazard class and, secondly, their degradation by digestive enzymes and nonspecific enzyme lysozyme. The latter property provides a natural removal of polymers from the oral cavity and gastrointestinal tract.
The use of high molecular weight complexes of boric acid reduces the side fiziologicheskii boron ions, and also enhance therapeutic effect with the gradual release of boric acid from the complex and the manifestation of a bacteriostatic effect. High mucoadhesives connection due to N,O-(2,3-dihydroxypropyl)chitosan provides high diffusion of the drug in the intercellular substance of damaged tissues and mucous membranes of the gastro-intestinal tract. Thus, the use of N,O-(2,3-dihydroxypropyl)chitosan-Borat can significantly reduce exposure of the main active substances (boric acid) and, therefore, to avoid adverse physiological reactions, providing a prolonged release of boron ions.
N,O-(2,3-dihydroxypropyl)chitosan-borate can be used as the main active component of the disinfectant, and as a Supplement to other antiseptic preparations, increasing their bactericidal effect. N,O-(2,3-dihydroxypropyl)chitosan-Borat not contain strong oxidizing agents, bases, aldehydes, aromatic alcohols, which provides him since it is hypoallergenic and no toxic reactions when administered orally. Does not cause allergic reactions and damaging effect on the skin, has no smell, has a long-lasting antimicrobial activity to the surface of things, can't cause different corrosion of materials. The presence of N,O-(2,3-dihydroxypropyl)of chitosan in the composition of the compounds provides a film formation on the treated subjects, which hampers the subsequent washout of N,O-(2,3-dihydroxypropyl)chitosan-borate, increases its bactericidal properties and duration of bactericidal activity of the drug on the treated surface.
N,O-(2,3-dihydroxypropyl)chitosan-borate, having the structural formula
SUBSTANCE: invention relates to producing chitosan from chitin and can be used in medicine, chemical, textile, paper and food industry. The method comprises crushing chitin to particle size of 1-2×2-3 mm; deacetylation of chitin in a double-neck reactor in 40% NaOH solution with in ratio to chitin of (1-3):(20-60) at 100°C, pressure of 300 mm Hg for 1-2 hours, wherein the double-neck reactor is fitted with a reflux condenser and is connected to a vacuum water-jet pump.
EFFECT: invention improves the degree of acetylation of chitosan and preserves the natural structure of the finished product.
2 tbl, 1 dwg
SUBSTANCE: there are described compositions containing hyaluronic acid with a low degree of modification of functional groups, and mixtures prepared by a controlled reaction of this slightly modified hyaluronic acid with applicable difunctional or polyfunctional cross-linking agents. The compositions possess the low anti-inflammatory properties in injection in vivo and can be used as medical devices, biomedical adhesives and sealing matters.
EFFECT: targeted delivery of the bioactive substances.
49 cl, 14 dwg, 24 tbl, 45 ex
SUBSTANCE: method of production of the water-soluble bioactive nanocomposite comprising salt of hyaluronic acid modified by citric acid or salt of citric acid, as a matrix, and gold nanoparticles as the filler is carried out by chemical interaction of solid-phase powders of salt of hyaluronic acid, citric acid or salt of citric acid and aurichlorohydric acid or salt of gold under the temperature from -18° to 125°C, under conditions of simultaneous action of pressure from 50 to 1000 MPa and the shear deformation in a mechanochemical reactor.
EFFECT: invention enables to obtain water-soluble bioactive nanocomposite with reliably predictable characteristics, namely the high yield of the target product, high gold content, controlled size of gold nanoparticles, narrow distribution by size of nanoparticles of gold, significant increase in resistance of the composite during long storage the above parameters of the composite are maintained for at least one year, the method is carried out in the absence of the liquid medium and does not require the stage of purification and concentration.
20 cl, 18 ex
SUBSTANCE: invention relates to natural polysaccharide polymers and can be used in medicine. The obtained water-soluble bioactive nanocomposite includes a melanin compound-modified hyaluronic acid salt as a matrix and gold nanoparticles as filler. The method includes chemical reaction of solid-phase hyaluronic acid powder, a melanin compound, aurichlorohydric acid or a gold salt in conditions of simultaneous pressure action in the range of 50 to 1000 MPa and shearing deformation in a mechanochemical reactor at temperature of -18° to 110°C.
EFFECT: invention enables to obtain a water-soluble bioactive nanocomposite with high output of the end product and high content of gold.
4 cl, 18 ex
SUBSTANCE: stabiliser includes modified chitosan which is obtained by modifying chitosan particles located in an emulsion of an organic solvent - water, with pH 6.0-6.5, by first reacting a mixture consisting of a carboxylic acid in an organic solvent and a condensing agent, and then with an organic base, wherein the carboxylic acid used is either palmitic acid or stearic acid or dodecanoic acid, the condensing agent used is a mixture of hydroxysuccinimide and an aliphatic carbodiimide or formaldehyde and an aliphatic isocyanide, and the organic base used is triethylamine.
EFFECT: effective liposome composition stabiliser which can be obtained using a simple method.
8 cl, 3 tbl, 5 ex, 7 dwg
SUBSTANCE: invention relates to the field of organic synthesis. A method of obtaining a water-insoluble sulphur-containing chitosan-based biopolymer includes interaction of chitosan with a thiomethylating agent, preliminarily obtained by saturation of a formaldehyde solution with gaseous H2S, with molar ratio chitosan: formaldehyde: hydrogen sulphide 1:6:4, at a temperature of 60°C for 20-25 hours.
EFFECT: invention ensures obtaining the water-insoluble sulphur-containing chitosan-based biopolymer, which possesses a complexing activity to ions of noble metals (Pd, Pt).
1 ex, 1 tbl
SUBSTANCE: skins of pond fish are flushed with cold flushing water during 10-15 minutes. They are crushed to the size of 2-3 mm. Water extraction is performed at the temperature of 40-45°C during 40-50 minutes at the ratio of crushed skins to water, which is equal to 1:1 at periodic mixing. Then, they are filtered; liquid fraction is dried in a spraying drier at the drier outlet product temperature of 60-65°C during 15-25 minutes so that hyaluronic acid is obtained. Solid fraction is subject to bleaching during 12 hours with hydrogen peroxide-salt solution that is prepared by mixing of 1 l of 3% hydrogen peroxide and 20 g of sodium chloride. Treatment of bleached solid fraction is performed with 1.0-1.2% solution of sodium hydroxide during 24 hours at the temperature of 20-25°C with further neutralisation of the obtained mixture with 3% boric acid solution. Treatment of swollen solid fraction is performed with Pancreatin ferment preparation solution taken in the quantity of 0.5-0.6% to the weight of solid fraction during 1.5-2.0 hours at the temperature of 37-40°C. Flushing of solid fraction is performed with cold flushing water for removal of Pancreatin residues so that collagen is obtained. The obtained collagen, depending on the purpose, is supplied for drying in drying chambers with forced air circulation at the temperature of 18-20°C during 12 hours and storage in dry ventilated rooms at the temperature of not higher than 20°C during 24 months or frozen to the temperature of minus 18 - minus 20°C and stored at the temperature of minus 18 - minus 20°C during 24 months. The liquid fraction dried in the spraying chamber is stored at the temperature of 0-4°C during 12 months or dissolved in physiological buffer solution.
EFFECT: improvement of the method.
2 dwg, 1 tbl, 1 ex
SUBSTANCE: production method of glucan-chitosan complex from yeast biomass of brewing waste involves mechanical and ultrasonic treatment of yeast biomass, destruction of proteins by treatment of the obtained suspension using alkali reagents with further extraction of a target product. As biomass, Saccharomyces living yeast is used. First, yeast is frozen to -15°C during 24 hours. After mechanical destruction, biomass is treated for 15 minutes at 20°C in an ultrasonic bath with frequency of an emitter of 35 kHz and voltage of 285 W. Biomass is acidified with chlorhydric acid till pH=5.5 and treated with ferment preparation in the amount of one pellet containing lipase - 3500 units of Ph.Eur., amylase - 4200 units of Ph.Eur. and protease - 250 units of Ph.Eur. per kilogramme of biomass in terms of dry substance; then, lipid components of yeast are removed. Fermentation is performed at t=20-29°C during 30-60 minutes. Destruction of proteins is performed at 55°C by means of a water bath during 60 minutes by treatment using 4% water solution of caustic soda at the ratio of yeast biomass and alkali, which is equal to 1:4. The medium is neutralised and hydrosol of glucan-chitosan complex is deposited by centrifugation during 10 minutes. The deposit is dried at t=55°C during 48 hours.
EFFECT: invention allows improving the quality of the obtained complex and its biological activity.
SUBSTANCE: invention relates to production of hydroxyalkyl derivatives of polysaccharides. The method of producing 2,3-dihydroxypropyl chitosan involves reacting chitosan with glycidol in the presence of hydrochloric acid with ratio glycidol:chitosan:hydrochloric acid = (2-6):1:1, at room temperature until a gel forms. The mixture is then heated at 55-65°C for 12-14 hours and the reaction mass is treated with water. The mixture is then deposited, subjected to hot extraction with water-soluble alcohols or ketones and dried.
EFFECT: invention simplifies the method of production and output of the end product and improves sorption properties of the compound.
1 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: there are presented: using benzophenanthridine alkaloid salts for preparing therapeutic agents for treating tumours, wherein the alkaloid salt is found in the form luteic, phosphatidic or hyaluronic acid, the benzophenanthridine alkaloid salt with phosphatidic acid or hyaluronic acid, and a based pharmaceutical composition for treating tumours.
EFFECT: what is shown is cytotoxic activity of the sanguinarine salts according to the invention at least twice increased in all studied tumour cell lines in relation to the chloride salt; it is suggested to be caused by higher absorption by the tumour cells.
12 cl, 8 ex
SUBSTANCE: invention relates to medicine and veterinary and is intended for the acceleration of stopping bleeding in case of injury to blood vessels in traumas and wounds. A haemostatic agent contains 3-20 wt % of a polysaccharide, where the polysaccharide is represented by chitosan and/or starch, 0.1-2 wt % of calcium chloride and a 0.5-5% water solution of succinic or hydrochloric acid - the remaining part.
EFFECT: accelerating the initiation of the thrombus-forming process and enhancement of the regenerative ability of tissues in the area of wounds of different aetiology.
1 tbl, 14 ex
SUBSTANCE: anti-tumour composition of a betulin derivative with a biocompatible carrier, wherein the betulin derivative is presented by betulin dipropionate, while the biocompatible carrier is arabinogalactane in certain proportions; the composition is prepared by a mechanic activation of betulin dipropionate with arabinogalactane.
EFFECT: composition possesses the pronounced anti-tumour activity and the improved solubility.
2 cl, 2 dwg, 4 tbl, 4 ex
SUBSTANCE: invention relates to radiation and experimental biology, biotechnology and medicine, namely to means of radiological protection and to stimulators of colony formation of stem cells. Invention can be used in research and clinical practice for protection of living organisms in case of exposure to ionising radiation, in emergency and military medicine, in case of emergency situations as means for protection against radiation injury. Claimed is application of preparation gamma-plant as radioprotector with colony-stimulating properties for increasing survival and improving state of organisms, subjected to irradiation. Gamma-plant is non-toxic polysaccharide of vegetable origin, registered by Ministry of Health of the Russian Federation and allowed for medical application; Gamma-plant is included into Russian Pharmacopoeia in section FG-9 "non-narcotic analgesics".
EFFECT: invention makes it possible to increase efficiency of colony formation of stem cells in spleen 2,0-2,3 times, increases survival of experimental animals to 95% with coefficient of dose reduction factor DRF, equal 2-2,2.
SUBSTANCE: invention is a composition having antibacterial, immunostimulating, anti-allergic and anti-inflammatory action, containing bacterial waste products useful for human body, in the form of exometabolites and fermentolysis products, characterised in that it is a culture medium of lactic acid bacteria, containing laxarane in an amount of 5-10 g/ml, caseicyne, isracydine or their mixture and lectins in an amount of 0.05-2.5 mol/l, histamine in an amount of 0.8-2.0 mmol/l and monocarboxylic fatty acid with an unbranched chain, namely, acetic acid, propionic acid, butyric acid and valeric acid - in an amount of 10-20 mg/ml.
EFFECT: expanding the range of agents having complementary antibacterial, immunomodulating, anti-allergic and anti-inflammatory action.
4 cl, 5 ex
SUBSTANCE: supramolecular complex, possessing an anti-inflammatory and angioprotective activity, which includes dihydroquercetin, arabinogalactan and water with a specified content of components. The method of obtaining the supramolecular complex includes mixing arabinoglactan with water to complete dissolution, then the addition of dihydroquercetin, heating the solution, mixing, with the following drying of the obtained solution by a method of spraying, under specified conditions.
EFFECT: increase of dihydroquercetin water solubility.
2 cl, 1 dwg, 5 tbl, 8 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to biotechnology. What is presented is an in vitro method for controlling a biofilm containing gram-negative bacteria, gram-positive bacteria or yeast, involving the contact of the above biofilm and an alginate oligomer. The alginate oligomer has an average molecular weight of less than 20000 Da and at least 80% of G residues, particularly α-L-guluronic acid. For the purpose of controlling the biofilm, including a biofilm infection, the above alginate oligomer can be also used as a part of a kit or a cleaning composition combined with other ingredients, as well as an abiotic surface coating.
EFFECT: above alginate oligomer can be used for preparing a therapeutic agent for using in treating or preventing the biofilm infection in an individual.
88 cl, 10 dwg, 7 tbl, 15 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the pharmaceutical industry, in particular to a peroral pharmaceutical composition, which contains polysaccharides from platyclades of Opuntia Ficus Indica, an extract of Olea Europeae leaves, alginate and sodium bicarbonate in a specified ratio. Components of the composition described above act with respect to reduction of gastroesophageal reflux.
EFFECT: peroral pharmaceutical composition is intended for the prevention and treatment of gastroesophageal reflux and GERD.
4 cl, 9 tbl, 6 dwg
SUBSTANCE: group of inventions relates to biotechnology and medicine. Disclosed is a polysaccharide which is isolated from the Bifidobacterium infantis NCIMB 41003 strain and has the structure [-β(1,3)-D-GalpNAc-β(1,4)-D-Glcp-]n, where said disaccharide unit repeats n times, which yields a polysaccharide with molecular weight greater than 100000 Da. The polysaccharide exhibits immunomodulating activity and is used in preparing medicinal agents for treating or preventing undesirable inflammatory activity, undesirable gastrointestinal inflammatory activity, rheumatoid arthritis and autoimmune disorders.
EFFECT: pharmaceutical composition for treating and preventing inflammatory disorders and a food product containing the isolated polysaccharide are disclosed.
9 cl, 6 dwg, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for preparing water-soluble fractions of mannoproteins and β-glucan. A method for preparing the water-soluble fractions of mannoproteins and β-glucan consisting in the fact that yeast biomass is prepared by mechanical activation in activators and mills; the prepared mechanical complex is added with a solution of enzymic complex showing β-glucanase or protease activity; that is followed by hydrolysis; the prepared hydrolysate is divided into mannoprotein and β-glucan fractions to be subject to purification under certain conditions.
EFFECT: method provides the more effective hydrolysis and higher yield of the end product.
2 cl, 4 dwg, 10 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry and represents pharmaceutical composition for treating gastroesophageal reflux disease, containing at least one proton pump inhibitor and at least one probiotic, wherein the proton pump inhibitor is taken in the amount of 0.05-25 wt % in the composition; and the probiotic is taken in the amount of 10-95 wt %; additive agents up to 100 wt %.
EFFECT: provided preventing Hpylori translocation, avoiding the necessity of Hpylori detection and antibacterial course of eradication, higher safety of the prolonged therapy with the proton pump inhibitors and avoided gastric mucosa atrophy, and a risk of gastric cancer.
5 cl, 10 tbl
FIELD: medicine, hematology, pharmaceutical technology, pharmacy.
SUBSTANCE: medicinal agent represents hydroxyethylated starch an aqueous solution containing 5-10% of hydroxyethylated starch with the optimal ratio of substituted hydroxyethyl groups at atoms C2/C6 up to 6:1 in glucose residue, average value of molecular mass 130-450 kDa, narrowed molecular-mass distribution at the substitution degree 0.35-0.70 and 0.80-1.00% of sodium chloride. Agent is prepared using maize or potato starch as the raw with the content of amylopectin 95%, not less. Starch is subjected for alkaline purification, acidic or enzymatic hydrolysis up to preparing products with molecular mass 400-900 kDa up to the required degree of substitution of hydroxyethyl groups. The solution is purified from impurities by ultrafiltration and/or reverse osmosis and purification is carried out using apyrogenic activated carbon and/or by sterilizing filtration and the following thermal sterilization of the end product. Invention provides preparing a new agent for rapid blood pressure recovery after blood loss.
EFFECT: improved preparing method, valuable medicinal properties of agent.
9 cl, 6 ex